サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1481919

アジア太平洋地域の乳がん治療：2030年までの市場予測 - 地域分析 - 薬物療法、乳がんタイプ、流通チャネル別

Asia Pacific Breast Cancer Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Therapy, Breast Cancer Type, and Distribution Channel

出版日
ページ情報
英文 106 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.69円
アジア太平洋地域の乳がん治療：2030年までの市場予測 - 地域分析 - 薬物療法、乳がんタイプ、流通チャネル別
出版日: 2024年03月04日
発行: The Insight Partners
ページ情報: 英文 106 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

アジア太平洋地域の乳がん治療市場は、2022年には69億8,637万米ドルと評価され、2030年には158億1,983万米ドルに達すると予測され、2022年から2030年までのCAGRは10.8%で成長すると予測されています。

複数の診断・スクリーニングプログラムの開始がアジア太平洋地域の乳がん治療市場を活性化

個別化医療、免疫療法、併用療法、ドラッグデリバリーシステム、リキッドバイオプシー、AI、患者中心のアプローチなどの進歩が、乳がん治療の将来を形成すると予想されます。これらの動向は、治療結果の改善、副作用の軽減、乳がん患者全体のQOLの向上を目指しています。

疾患の早期発見は、患者の転帰と生存率の改善に大きな役割を果たします。様々な組織やヘルスケアプロバイダーが、乳がんを治療可能な初期段階で発見するための検診プログラムを実施しています。世界保健機関（WHO）は2013年2月、2040年までに250万人を乳がんから救うという目標を達成するための計画として、新たな「世界乳がんイニシアチブフレームワーク」を発表しました。これを達成するために、世界がんデーキャンペーンに先駆けて発表された新フレームワークは、乳がんの早期発見、迅速な診断、徹底した管理のための健康増進の3本柱に従うよう各国に促しています。これらのプログラムには、乳がんの異常や徴候を発見するためのマンモグラフィ、乳房臨床検査、自己乳房検診が含まれることが多いです。このようなプログラムを実施することにより、乳がんに対する認識と早期発見が高まり、効果的な治療薬に対する需要が高まっています。

さらに、診断技術の進歩も世界中で多く見られるようになった。国立医学図書館は、早期発見と正確な診断が予後を改善するために不可欠であると述べています。乳がんの評価には、デジタルマンモグラフィ（DM）、デジタルブレストトモシンセシス（DBT）、磁気共鳴画像法（MRI）、超音波法（米国）、核医学検査などのX線画像診断法が頻繁に用いられています。病理組織検査（HP）は、がんの有無を判定するためのゴールドスタンダードです。さらに、人工知能（AI）技術を用いて医療画像を定量的に描写することは、乳がんのセグメンテーション、診断、予後を改善する大きな可能性を秘めています。これらの技術は、ヘルスケア提供者が腫瘍の範囲や特徴を特定するのに役立ち、個別化された治療計画を立てることを可能にします。このように、診断およびスクリーニングプログラムの開始と診断技術の進歩は、アジア太平洋地域の乳がん治療市場の成長に寄与しています。

アジア太平洋地域の乳がん治療市場概要

アジア太平洋地域の乳がん治療市場は、中国、日本、インド、韓国、オーストラリア、その他アジア太平洋地域に区分されます。市場の成長は、個別化医療、免疫療法、併用療法、ドラッグデリバリーシステムの進歩に加え、女性の乳がん負担の増加などの要因によるものです。

中国の乳がん治療市場は、乳がん有病率の上昇、高齢化人口の増加、ライフスタイルの変化などに起因して、今後数年間で大幅な成長を示すと予測されています。2023年4月14日に発表されたCDCの統計によると、中国は2020年に世界で新たに診断された症例の24％、がんに関連した死亡例の30％を占めています。過去30年間で、乳がんの年齢標準化罹患率は1990年の10万人当たり17.07人から2019年には10万人当たり35.61人に上昇しました。治療オプションの進歩は、中国における乳がん治療薬の需要を促進する上で重要な役割を果たしています。

また、日本では女性の10人に1人が乳がんにかかると言われています。10月のピンクリボンキャンペーンやその他の取り組みにより、セルフチェックやその他の早期発見法の重要性など、日本人の乳がんに対する意識が高まっており、これらの方法を用いれば生存率は90％以上に高まる。しかし、代表的なリスク変数の特定は遅れています。このように、日本の乳がん治療市場は、高齢化、治療法の選択肢、政府の取り組みや政策、高いヘルスケア支出、意識の高まり、技術の進歩などにより、大きく成長すると予想されます。

アジア太平洋地域の乳がん治療市場の収益と2030年までの予測（金額）

アジア太平洋地域の乳がん治療市場のセグメンテーション

アジア太平洋地域の乳がん治療市場は、薬物療法、乳がんのタイプ、流通チャネルに基づいてセグメント化されます。

薬物療法に基づき、アジア太平洋地域の乳がん治療市場は標的薬物療法、ホルモン薬物療法、化学療法、免疫療法/生物学的療法に区分されます。2022年には標的薬物療法分野がより大きなシェアを占めました。標的薬物療法セグメントは2022年に大きなシェアを占めました。標的薬物療法セグメントはさらに、アベマシクリブ、アドトラスツズマブ・エムタンシン、パルボシクリブ、トラスツズマブ、その他の標的薬物療法に細分化されます。さらに、ホルモン薬物療法セグメントは、選択的エストロゲン受容体モジュレーター、アロマターゼ阻害剤、選択的エストロゲン受容体ダウンレギュレーターに分類されます。

乳がんのタイプ別では、アジア太平洋地域の乳がん治療市場はホルモン受容体、HER2+、トリプルネガティブ乳がんに区分されます。2022年にはホルモン受容体セグメントがより大きなシェアを占めています。

流通チャネル別では、アジア太平洋地域の乳がん治療市場は病院薬局、ドラッグストア・小売薬局、オンライン薬局に区分されます。2022年には病院薬局セグメントが大きなシェアを占めています。

国別に見ると、アジア太平洋地域の乳がん治療市場は、オーストラリア、中国、インド、日本、韓国、その他アジア太平洋地域に分類されます。2022年のアジア太平洋地域の乳がん治療市場は中国が支配的でした。

Eli Lilly and Co、Eisai Co Ltd、Novartis AG、AstraZeneca Plc、Pfizer Inc、Gilead Sciences Inc、Merck &Co Inc、Teva Pharmaceutical Industries Ltd、Amgen IncおよびAmgen Incは、アジア太平洋地域の乳がん治療市場で事業を展開している大手企業です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要な洞察

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 アジア太平洋地域の乳がん治療市場- 主要産業力学

  • 主な市場促進要因
    • 乳がんの負担増
    • 複数の診断およびスクリーニングプログラムの開始
  • 主な市場抑制要因
    • 診断と治療にかかるコストの高さ
  • 主な市場機会
    • 政府および民間団体からの支援の増加
  • 主な将来動向
    • 個別化医療の利用の増加
  • 影響分析

第5章 乳がん治療市場：アジア太平洋地域市場分析

  • アジア太平洋地域の乳がん治療市場収益、2022年～2030年

第6章 アジア太平洋地域の乳がん治療市場 - 収益と2030年までの予測：薬物療法別

  • 市場収益シェア、2022年および2030年
  • 標的薬物療法
  • ホルモン薬物療法
  • 化学療法
  • 免疫療法/生物学的療法

第7章 アジア太平洋地域の乳がん治療市場 - 収益と2030年までの予測：乳がんタイプ別

  • 市場収益シェア、2022年および2030年
  • ホルモン受容体
  • HER2+（ヒト上皮成長因子受容体2）
  • トリプルネガティブ乳がん

第8章 アジア太平洋地域の乳がん治療市場 - 収益と2030年までの予測：流通チャネル別

  • 市場収益シェア、2022年および2030年
  • 病院薬局
  • ドラッグストアおよび小売薬局
  • オンライン薬局

第9章 アジア太平洋地域の乳がん治療市場：国別分析

  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国
  • その他アジア太平洋地域

第10章 乳がん治療市場：業界情勢

  • 乳がん治療市場における成長戦略
  • 有機的成長戦略
  • 無機的成長戦略

第11章 企業プロファイル

  • Eli Lilly and Co
  • Eisai Co Ltd
  • Novartis AG
  • AstraZeneca Plc
  • Pfizer Inc
  • Gilead Sciences Inc
  • Merck & Co Inc
  • Teva Pharmaceutical Industries Ltd
  • Amgen Inc

第12章 付録

図表

List Of Tables

  • Table 1. Asia Pacific Breast Cancer Therapeutics Market Segmentation
  • Table 2. Asia Pacific Breast Cancer Therapeutics Market, by Targeted Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 3. Asia Pacific Breast Cancer Therapeutics Market, by Hormonal Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 4. China Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 5. China Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 6. China Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 7. China Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 8. China Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
  • Table 9. Japan Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 10. Japan Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 11. Japan Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 12. Japan Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 13. Japan Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
  • Table 14. India Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 15. India Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 16. India Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 17. India Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 18. India Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
  • Table 19. Australia Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 20. Australia Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 21. Australia Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 22. Australia Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 23. Australia Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
  • Table 24. South Korea Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 25. South Korea Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 26. South Korea Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 27. South Korea Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 28. South Korea Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
  • Table 29. Rest of Asia Pacific Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 30. Rest of Asia Pacific Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 31. Rest of Asia Pacific Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 32. Rest of Asia Pacific Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 33. Rest of Asia Pacific Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
  • Table 34. Recent Organic Growth Strategies in Breast Cancer Therapeutics Market
  • Table 35. Recent Inorganic Growth Strategies in the Breast Cancer Therapeutics Market
  • Table 36. Glossary of Terms, Breast Cancer Therapeutics Market

List Of Figures

  • Figure 1. Asia Pacific Breast Cancer Therapeutics Market Segmentation, By Country
  • Figure 2. Asia Pacific Breast Cancer Therapeutics Market - Key Industry Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Asia Pacific Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030
  • Figure 5. Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
  • Figure 6. Targeted Drug Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Hormonal Drug Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Chemotherapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Immunotherapy/ Biological Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
  • Figure 11. Hormone Receptor: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. HER2+: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Triple-Negative Breast Cancer: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
  • Figure 15. Hospital Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Drug Store and Retail Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Online Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Asia Pacific Breast Cancer Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 19. Asia Pacific Breast Cancer Therapeutics Market, By Key Countries, 2022 and 2030 (%)
  • Figure 20. China Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 21. Japan Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 22. India Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 23. Australia Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 24. South Korea Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 25. Rest of Asia Pacific Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 26. Growth Strategies in Breast Cancer Therapeutics Market
目次
Product Code: BMIRE00029749

The Asia Pacific breast cancer therapeutics market was valued at US$ 6,986.37 million in 2022 and is expected to reach US$ 15,819.83 million by 2030; it is estimated to grow at a CAGR of 10.8% from 2022 to 2030.

Launch of Several Diagnostics and Screening Programs Fuels the Asia Pacific Breast Cancer Therapeutics Market

Advancements in personalized medicine, immunotherapy, combination therapies, drug delivery systems, liquid biopsies, AI, and patient-centric approaches are expected to shape the future of breast cancer treatment. These trends aim to improve treatment outcomes, reduce side effects, and enhance breast cancer patients overall quality of life.

Early disease detection plays a major role in improving patient outcomes and survival rates. Various organizations and healthcare providers are implementing screening programs to detect breast cancer at an initial stage when it is more treatable. The World Health Organization released a new Global Breast Cancer Initiative Framework in February 2013 that serves as a plan for fulfilling the goal of saving 2.5 million people from breast cancer by 2040. To achieve this, the new Framework, unveiled ahead of the World Cancer Day campaign, urges nations to follow the three pillars of health promotion for early detection, prompt diagnosis, and thorough management of breast cancer. These programs often include mammography, clinical breast exams, and self-breast exams to identify any abnormalities or signs of breast cancer. Implementing these programs has increased awareness and early detection of breast cancer cases, resulting in higher demand for effective therapeutics.

In addition, many advancements in diagnostic technologies have been witnessed across the globe. The National Library of Medicine states that early detection and precise diagnosis are essential for enhancing prognosis. Breast cancer assessment frequently makes use of radiographic imaging modalities such as digital mammography (DM), digital breast tomosynthesis (DBT), magnetic resonance imaging (MRI), ultrasound (US), and nuclear medicine procedures. Histopathology (HP) is the gold standard for determining the presence of cancer. Furthermore, using artificial intelligence (AI) technology to depict medical images quantitatively has significant potential for improving breast cancer segmentation, diagnosis, and prognosis. These technologies help healthcare providers identify the extent and characteristics of the tumor, allowing them to develop personalized treatment plans. Thus, the launch of diagnostic and screening programs, coupled with advancements in diagnostic technologies, contributes to the Asia Pacific breast cancer therapeutics market growth.

Asia Pacific Breast Cancer Therapeutics Market Overview

The breast cancer therapeutics market in Asia Pacific is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The market growth is attributed to factors including growing burden of breast cancers among women coupled with advancements in personalized medicine, immunotherapy, combination therapies, and drug delivery systems.

The breast cancer therapeutics market in China is projected to witness substantial growth in the coming years, owing to the rising prevalence of breast cancer, increasing aging population, lifestyle changes, and others. China accounted for 24% of cases with new diagnoses and 30% of cancer-related fatalities globally in 2020, as per CDC statistics published on April 14, 2023. Over the last three decades, the age-standardized incidence of breast cancer climbed from 17.07 per 100,000 in 1990 to 35.61 per 100,000 in 2019. Advancements in treatment options have played a crucial role in driving the demand for breast cancer therapeutics in China.

Also, out of 1 in 10 women in Japan will acquire breast cancer at some point. The pink ribbon campaign in October and other initiatives have raised awareness of the disease among Japanese people, including the importance of self-checks and other early detection methods that, when used, increase the survival rate to over 90%. The identification of typical risk variables, however, lags. Thus, the breast cancer therapeutics market in Japan is expected to grow significantly due to an aging population, treatment options, government initiatives and policies, high healthcare expenditure, rising awareness, and technological advancements.

Asia Pacific Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Breast Cancer Therapeutics Market Segmentation

The Asia Pacific breast cancer therapeutics market is segmented based on drug therapy, breast cancer type, and distribution channel.

Based on drug therapy, the Asia Pacific breast cancer therapeutics market is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment is further subsegmented into abemaciclib, ado-trastuzumab emtansine, palbociclib, trastuzumab, and other target drug therapy. Additionally, the hormonal drug therapy segment is categorized into selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor downregulators.

In terms of breast cancer type, the Asia Pacific breast cancer therapeutics market is segmented into hormone receptor, HER2+, and triple-negative breast cancer. The hormone receptor segment held a larger share in 2022.

By distribution channel, the Asia Pacific breast cancer therapeutics market is segmented into hospital pharmacies, drug store and retail pharmacies, and online pharmacies. The hospital pharmacies segment held a larger share in 2022.

Based on country, the Asia Pacific breast cancer therapeutics market is categorized into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific breast cancer therapeutics market in 2022.

Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc and Amgen Inc are some of the leading companies operating in the Asia Pacific breast cancer therapeutics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Asia Pacific Breast Cancer Therapeutics Market - Key Industry Dynamics

  • 4.1 Key Market Drivers
    • 4.1.1 Growing Burden of Breast Cancer
    • 4.1.2 Launch of Several Diagnostics and Screening Programs
  • 4.2 Key Market Restraints
    • 4.2.1 High Cost of Diagnosis and Treatment
  • 4.3 Key Market Opportunities
    • 4.3.1 Increased Support from Government and Private Organizations
  • 4.4 Key Future Trends
    • 4.4.1 Increasing Use of Personalized Medicine
  • 4.5 Impact Analysis:

5. Breast Cancer Therapeutics Market - Asia Pacific Market Analysis

  • 5.1 Asia Pacific Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030

6. Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Drug Therapy

  • 6.1 Overview
  • 6.2 Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
  • 6.3 Targeted Drug Therapy
    • 6.3.1 Overview
    • 6.3.2 Targeted Drug Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
      • 6.3.2.1 Asia Pacific Breast Cancer Therapeutics Market, by Targeted Drug Therapy, 2020-2030 (US$ Million)
  • 6.4 Hormonal Drug Therapy
    • 6.4.1 Overview
    • 6.4.2 Hormonal Drug Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
      • 6.4.2.1 Asia Pacific Breast Cancer Therapeutics Market, by Hormonal Drug Therapy, 2020-2030 (US$ Million)
  • 6.5 Chemotherapy
    • 6.5.1 Overview
    • 6.5.2 Chemotherapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.6 Immunotherapy/ Biological Therapy
    • 6.6.1 Overview
    • 6.6.2 Immunotherapy/ Biological Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Breast Cancer Type

  • 7.1 Overview
  • 7.2 Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
  • 7.3 Hormone Receptor
    • 7.3.1 Overview
    • 7.3.2 Hormone Receptor: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 HER2+ (human epidermal growth factor receptor 2)
    • 7.4.1 Overview
    • 7.4.2 HER2+: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Triple-Negative Breast Cancer
    • 7.5.1 Overview
    • 7.5.2 Triple-Negative Breast Cancer: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Distribution Channel

  • 8.1 Overview
  • 8.2 Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
  • 8.3 Hospital Pharmacies
    • 8.3.1 Overview
    • 8.3.2 Hospital Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Drug Store and Retail Pharmacies
    • 8.4.1 Overview
    • 8.4.2 Drug Store and Retail Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Online Pharmacies
    • 8.5.1 Overview
    • 8.5.2 Online Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Breast Cancer Therapeutics Market -Country Analysis

  • 9.1 Asia Pacific Breast Cancer Therapeutics Market, Revenue and Forecast to 2030
    • 9.1.1 Overview
    • 9.1.2 Asia Pacific Breast Cancer Therapeutics Market, Breakdown, by Country- Revenue (2022) (US$ Million)
    • 9.1.3 Asia Pacific Breast Cancer Therapeutics Market, by Countries, 2022 and 2030 (%)
      • 9.1.3.1 China
        • 9.1.3.1.1 China Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.3.1.2 China: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.1.2.1 China: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.1.2.2 China: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.1.3 China: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
        • 9.1.3.1.4 China: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
      • 9.1.3.2 Japan
        • 9.1.3.2.1 Japan Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.3.2.2 Japan: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.2.2.1 Japan: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.2.2.2 Japan: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.2.3 Japan: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
        • 9.1.3.2.4 Japan: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
      • 9.1.3.3 India
        • 9.1.3.3.1 India Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.3.3.2 India: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.3.2.1 India: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.3.2.2 India: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.3.3 India: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
        • 9.1.3.3.4 India: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
      • 9.1.3.4 Australia
        • 9.1.3.4.1 Australia Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.3.4.2 Australia: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.4.2.1 Australia: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.4.2.2 Australia: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.4.3 Australia: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
        • 9.1.3.4.4 Australia: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
      • 9.1.3.5 South Korea
        • 9.1.3.5.1 South Korea Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.3.5.2 South Korea: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.5.2.1 South Korea: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.5.2.2 South Korea: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.5.3 South Korea: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
        • 9.1.3.5.4 South Korea: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
      • 9.1.3.6 Rest of Asia Pacific
        • 9.1.3.6.1 Rest of Asia Pacific Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.3.6.2 Rest of Asia Pacific: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.6.2.1 Rest of Asia Pacific: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.6.2.2 Rest of Asia Pacific: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.6.3 Rest of Asia Pacific: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
        • 9.1.3.6.4 Rest of Asia Pacific: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)

10. Breast Cancer Therapeutics Market-Industry Landscape

  • 10.1 Overview
  • 10.2 Growth Strategies in Breast Cancer Therapeutics Market
  • 10.3 Organic Growth Strategies
    • 10.3.1 Overview
  • 10.4 Inorganic Growth Strategies
    • 10.4.1 Overview

11. Company Profiles

  • 11.1 Eli Lilly and Co
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 Eisai Co Ltd
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Novartis AG
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 AstraZeneca Plc
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Pfizer Inc
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Gilead Sciences Inc
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Merck & Co Inc
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Teva Pharmaceutical Industries Ltd
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Amgen Inc
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments

12. Appendix

  • 12.1 About Us
  • 12.2 Glossary of Terms